| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 406.36 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Introduction: From September to November 2025, many European countries launched COVID-19 vaccination campaigns, when SARS-CoV-2 incidence was decreasing after a period of high circulation.1 These campaigns targeted specific groups, including older adults (ie, individuals aged at or above a minimum threshold that varied from age 60 to 70 years across countries). We estimated the effectiveness of COVID-19 vaccines administered during these seasonal vaccination campaigns in Europe against medically attended, symptomatic SARS-CoV-2 infection among older adults, from September 29, 2025, to January 10, 2026.
Plain language summary: This case-control study examines COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection among older adults in Europe.
Plain language summary: This case-control study examines COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection among older adults in Europe.
Descrição
Research Letter
The VEBIS Primary Care Vaccine Effectiveness Group Investigators and Coordinators: João Almeida Santos, Licínia Gomes, Ausenda Machado, Raquel Guiomar (INSA).
The VEBIS Primary Care Vaccine Effectiveness Group Investigators and Coordinators: João Almeida Santos, Licínia Gomes, Ausenda Machado, Raquel Guiomar (INSA).
Palavras-chave
COVID‐19 SARS‐CoV‐2 Vaccine Effectiveness VEBIS Cuidados de Saúde Infecções Respiratórias
Contexto Educativo
Citação
JAMA Netw Open. 2026 Jun 1;9(6):e2619040. doi: 10.1001/jamanetworkopen.2026.19040
Editora
American Medical Association